Kymera Therapeutics (NASDAQ:KYMR) had its "buy" rating reaffirmed by analysts at B. Riley.
Kymera Therapeutics (NASDAQ:KYMR) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. [Yahoo! Finance]
Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Kymera gains Fast Track status for oral candidate KT-621 for eczema [Seeking Alpha]